JP2010522141A5 - - Google Patents

Download PDF

Info

Publication number
JP2010522141A5
JP2010522141A5 JP2009546461A JP2009546461A JP2010522141A5 JP 2010522141 A5 JP2010522141 A5 JP 2010522141A5 JP 2009546461 A JP2009546461 A JP 2009546461A JP 2009546461 A JP2009546461 A JP 2009546461A JP 2010522141 A5 JP2010522141 A5 JP 2010522141A5
Authority
JP
Japan
Prior art keywords
molecule
seq
chain variable
variable region
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009546461A
Other languages
English (en)
Japanese (ja)
Other versions
JP5307030B2 (ja
JP2010522141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/050554 external-priority patent/WO2008088983A1/en
Publication of JP2010522141A publication Critical patent/JP2010522141A/ja
Publication of JP2010522141A5 publication Critical patent/JP2010522141A5/ja
Application granted granted Critical
Publication of JP5307030B2 publication Critical patent/JP5307030B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009546461A 2007-01-18 2008-01-09 ＰＥＧ化ＡβＦＡＢ Expired - Fee Related JP5307030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88543907P 2007-01-18 2007-01-18
US60/885,439 2007-01-18
PCT/US2008/050554 WO2008088983A1 (en) 2007-01-18 2008-01-09 PEGYLATED Aβ FAB

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013133551A Division JP5782479B2 (ja) 2007-01-18 2013-06-26 ＰＥＧ化ＡβＦＡＢ

Publications (3)

Publication Number Publication Date
JP2010522141A JP2010522141A (ja) 2010-07-01
JP2010522141A5 true JP2010522141A5 (Direct) 2011-02-10
JP5307030B2 JP5307030B2 (ja) 2013-10-02

Family

ID=39332186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009546461A Expired - Fee Related JP5307030B2 (ja) 2007-01-18 2008-01-09 ＰＥＧ化ＡβＦＡＢ
JP2013133551A Expired - Fee Related JP5782479B2 (ja) 2007-01-18 2013-06-26 ＰＥＧ化ＡβＦＡＢ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013133551A Expired - Fee Related JP5782479B2 (ja) 2007-01-18 2013-06-26 ＰＥＧ化ＡβＦＡＢ

Country Status (26)

Country Link
US (1) US8066999B2 (Direct)
EP (2) EP2121754B1 (Direct)
JP (2) JP5307030B2 (Direct)
KR (2) KR101160385B1 (Direct)
CN (2) CN101981053B (Direct)
AR (1) AR064944A1 (Direct)
AU (1) AU2008206555B2 (Direct)
BR (1) BRPI0806715A2 (Direct)
CA (1) CA2675847C (Direct)
CL (1) CL2008000121A1 (Direct)
CY (2) CY1116157T1 (Direct)
DK (1) DK2121754T3 (Direct)
EA (1) EA020979B1 (Direct)
ES (2) ES2535641T3 (Direct)
HR (2) HRP20150237T1 (Direct)
IL (2) IL199838A (Direct)
LT (1) LT2842967T (Direct)
MX (1) MX2009007691A (Direct)
PE (1) PE20081634A1 (Direct)
PL (1) PL2121754T3 (Direct)
PT (2) PT2842967T (Direct)
RS (1) RS53948B1 (Direct)
SI (2) SI2842967T1 (Direct)
TW (1) TW200836763A (Direct)
UA (1) UA95996C2 (Direct)
WO (1) WO2008088983A1 (Direct)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101784231B1 (ko) 2008-06-20 2017-11-08 노파르티스 아게 응집이 감소된 면역글로불린
PL2310970T3 (pl) 2008-06-20 2013-10-31 Novartis Ag Metody identyfikacji w białkach regionów wiązania makrocząsteczek i regionów podatności na agregację i zastosowanie tych metod
PL2896404T3 (pl) 2009-06-04 2017-12-29 Novartis Ag Sposoby identyfikacji miejsc koniugacji IgG
MX2012009460A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Int Polipeptidos biparatopicos de union abeta.
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
US10431325B2 (en) 2012-08-03 2019-10-01 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
WO2015036553A1 (en) * 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
KR20150133576A (ko) 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
WO2017079833A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
WO2017079835A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
HK1259325A1 (zh) 2015-11-09 2019-11-29 英属哥伦比亚大学 淀粉样蛋白β中的N-末端表位及其构象选择性抗体
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
WO2018014126A1 (en) 2016-07-18 2018-01-25 The University Of British Columbia Antibodies to amyloid beta
CN109562167A (zh) 2016-08-09 2019-04-02 伊莱利利公司 联合治疗
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
JP7330164B2 (ja) 2017-07-18 2023-08-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
WO2019134039A1 (en) * 2018-01-04 2019-07-11 Septa Therapeutics, Inc. Septapeptides associated with neurodegeneracy
JP2022523333A (ja) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体およびその使用
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5278049A (en) * 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5445090A (en) 1991-07-25 1995-08-29 Mim Industries, Inc. Interchangeable clamp for use in a sewing machine
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU692237B2 (en) * 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5668651A (en) * 1994-03-18 1997-09-16 Sharp Kabushiki Kaisha Polymer-wall LCD having liquid crystal molecules having a plane-symmetrical bend orientation
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US20040121415A1 (en) * 1996-12-10 2004-06-24 King David John Monovalent antibody fragments
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6413940B1 (en) 1997-02-07 2002-07-02 Nymox Corporation Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
DK0994728T3 (da) 1997-04-09 2008-12-01 Intellect Neurosciences Inc Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
US6787319B2 (en) * 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6227999B1 (en) 1997-07-09 2001-05-08 Transmisiones Tsp, S.A. De C.V. Method and apparatus for operating a clutch in an automated mechanical transmission
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
EP0996736A1 (en) * 1997-08-11 2000-05-03 Chiron Corporation Methods for genetically modifying t cells
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
CA2325600A1 (en) 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Methods for amyloid removal using anti-amyloid antibodies
ES2312348T3 (es) * 1999-06-16 2009-03-01 Boston Biomedical Research Institute Control inmunologico de niveles de beta-amiloide in vivo.
AU6524500A (en) 1999-08-04 2001-03-05 Northwestern University Amyloid beta protein (globular assembly and uses thereof)
ATE461996T1 (de) 1999-09-03 2010-04-15 Univ Ramot Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
DE60026073T2 (de) 1999-12-22 2006-09-28 Nektar Therapeutics Al, Corp., Huntsville Sterisch gehinderte derivate von wasserlöslichen polymeren
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
DZ3295A1 (fr) * 2000-02-24 2001-08-30 Anticorps humanises sequestrant un peptide amyloide .beta.
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
AU2001290638C1 (en) 2000-09-06 2009-04-30 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2004081026A2 (en) * 2003-06-30 2004-09-23 Domantis Limited Polypeptides
US20040241164A1 (en) * 2001-08-17 2004-12-02 Bales Kelly Renee Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
EP1519740A4 (en) 2001-08-17 2005-11-09 Lilly Co Eli FASTER IMPROVEMENT OF COGNITION IN DISEASES ASSOCIATED WITH A-BETA
AU2002329775C1 (en) * 2001-08-17 2011-04-07 Eli Lilly And Company Assay method for alzheimer's disease
ATE381346T1 (de) 2001-08-17 2008-01-15 Univ Washington Assayverfahren für alzheimer-krankheit
US7166478B2 (en) * 2002-03-12 2007-01-23 Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses
WO2003090772A1 (en) 2002-04-25 2003-11-06 Eli Lilly And Company Method for treating anxiety and mood disorders in older subjects
DE60329627D1 (de) * 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
EP1596809B1 (en) * 2003-02-10 2010-05-26 Applied Molecular Evolution, Inc. Abeta binding molecules
KR20070084170A (ko) * 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion

Similar Documents

Publication Publication Date Title
JP2010522141A5 (Direct)
HRP20161677T1 (hr) Pegilirani fab protiv amiloida beta
HRP20170110T1 (hr) Monoklonska protutijela
EA201000809A1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
ME02352B (me) PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA
CY1113630T1 (el) Αντισωματα αντι-χεπσιδινης και χρησεις εξ αυτωn
JP2013524774A5 (Direct)
CY1120014T1 (el) Αντισωματα συνδεσης πρωτοϊνιδιου και χρηση αυτων σε θεραπευτικες και διαγνωστικες μεθοδους για ασθενεια parkinson, ανοια με σωματα lewy και αλλες αλφα-συνουκλεϊνοπαθειες
JP2013525266A5 (Direct)
IL319612A (en) Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
RU2534564C3 (ru) Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
JP2006522830A5 (Direct)
JP2013538796A5 (Direct)
JP2011528561A5 (Direct)
MX2009009226A (es) Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.
JP2010539921A5 (Direct)
WO2010012004A3 (en) Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
RU2010119521A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2014508748A5 (Direct)
JP2010202664A5 (Direct)
EA201190018A1 (ru) Миостатинсвязывающие белки
WO2006110214A3 (en) Antibodies against mammalian metapneumovirus
JP2010513327A5 (Direct)
CR20120491A (es) Proteinas de unión a antigeno especificas para el componente amiloide serico p